Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

PHASE2CompletedINTERVENTIONAL
Enrollment

316

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

November 23, 2023

Study Completion Date

November 23, 2023

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

Ipilimumab plus nivolumab

Ipilimumab every 3 weeks for 4 times Nivolumab every 3 weeks for 4 times followed by maintenance therapy with nivolumab every 2nd or 4th week

DRUG

Standard Therapy

Standard of Care therapy is administered according to the physician´s decision.

Trial Locations (30)

30625

Medizinische Hochschule Hannover, Hanover

48149

University of Muenster, Münster

69120

Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg

91054

University Hospital Erlangen, Erlangen

Unknown

Gent University Hospital (Universitair Ziekenhuis Gent), Ghent

University Hospital Hradec Králové, Hradec Králové

Thomayer Hospital, Prague

Centre Hospitalier Universitaire de Bordeaux, Bordeaux

Centre François Baclesse, Caen

Centre Hospitalier Départemental de Vendée, La Roche-sur-Yon

Centre Leon Berard, Lyon

Institut Gustave Roussy, Paris

Les Hoptaux Universitaires de Strasbourg, Strasbourg

Charite Berlin (Campus Virchow-Klinikum), Berlin

Heine University, Düsseldorf

Universitätsklinikum Essen, Essen

University Hospital Greifswald, Greifswald

University Hospital, Homburg/Saar

Klinik für Urologie, Universitätsklinik, Jena

Klinikum Rechts der Isar der TU München, München

Universitätsklinik Tübingen, Tübingen

Netherlands Cancer Institute, Amsterdam

University Medical Center Groningen, Groningen

Hospita de la Santa Creu i Sant Pau, Barcelona

Hospital Clinic de Barcelona, Barcelona

Hospital Vall d'Hebron, Barcelona

Hospital Univeritario 12 de Octubre, Madrid

Royal Free London NHS Foundation Trust, London

The Christie NHS Foundation Trust, Manchester

D-60590

Goethe University Frankfurt, Frankfurt am Main

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Goethe University

OTHER